A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ALKS 2680 IN ADULTS WITH NARCOLEPSY TYPE 1

Registry ID

ALKS 2680-304

Source registry

HEALTH_CANADA

Status

Pending

Phase

PHASE3

Study type

INTERVENTIONAL

Sponsor

ALKERMES INC

Last update

2026-05-07

Conditions

• NARCOLEPSY

Related clinical trials

• A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ALKS 2680 IN ADULTS WITH NARCOLEPSY TYPE 1
• A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF E2086 IN ADULTS WITH NARCOLEPSY
• A LONG-TERM EXTENSION STUDY OF THE SAFETY AND EFFICACY OF CLEMINOREXTON IN PARTICIPANTS WITH NARCOLEPSY AND IDIOPATHIC HYPERSOMNIA WHO COMPLETED A SPONSORED CLEMINOREXTON CLINICAL TRIAL
• A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY OF THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF ORX750 IN SUBJECTS WITH NARCOLEPSY AND IDIOPATHIC HYPERSOMNIA ¿ (CRYSTAL-1)
• A LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF TAK-861 IN PARTICIPANTS WITH SELECTED CENTRAL HYPERSOMNIA CONDITIONS
• A STUDY TO ASSESS THE LONG-TERM EFFICACY AND SAFETY OF AXS-12 IN THE TREATMENT OF CATAPLEXY AND EXCESSIVE DAYTIME SLEEPINESS IN SUBJECTS WITH NARCOLEPSY

View on source registry